All In MedTech

Device Trial Radar · NCT04381728

PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

23

Actual

Start

Nov 18, 2019

Primary completion

Mar 15, 2021

Study completion Mar 15, 2021

Sponsor

Lead sponsor
WomedNot on our public-company list
Sponsor type
Industry
First posted
May 11, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
Female only, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Intrauterine adhesions (IUA) are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complication and infertility. Womed Leaf is a medical device specifically designed for intrauterine use that prevents intra-uterine adhesions. It is a film that acts as a mechanical barrier to keep uterus walls separated during healing. It is then naturally discharged through the cervix and vagina in less than 30 days. The PREG1 clinical investigation is designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy.

Conditions

  • Intrauterine Adhesion

Interventions

  • Womed LeafDevice

    Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (Adverse Events)Time frame: 30 days
  2. Efficacy (Rate of Patient With no IUA)Time frame: At second look hysteroscopy between 4 and 8 weeks
  3. Efficacy (Intrauterine Adhesion Severity According to AFS Classification)Time frame: At second look hysteroscopy between 4 and 8 weeks

1 more outcomes with a free account

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • UZ Gent

    Ghent, Belgium

  • CHU Nîmes

    Nîmes, France

  • CHU Bicêtre (APHP)

    Paris, France

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.